Risk Factors for Major Bleeding and Clinically Relevant Non-major Bleeding in Japanese Patients Treated with Edoxaban
| Autor: | Tomoki Takase, Nobuyuki Muroi, Yutaka Furukawa, Haruna Nakagawa, Hiroaki Ikesue, Takeshi Kitai, Tohru Hashida, Megumi Kinoshita |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Pyridines Pharmaceutical Science Renal function Hemorrhage 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Japan Risk Factors Edoxaban Internal medicine medicine Humans Risk factor Stroke Aged Retrospective Studies Pharmacology business.industry Proportional hazards model Hazard ratio General Medicine Middle Aged medicine.disease Confidence interval Thiazoles 030104 developmental biology chemistry 030220 oncology & carcinogenesis Female business Complication Factor Xa Inhibitors |
| Zdroj: | Biological and Pharmaceutical Bulletin. 43:458-462 |
| ISSN: | 1347-5215 0918-6158 |
| DOI: | 10.1248/bpb.b19-00799 |
| Popis: | Edoxaban is used to prevent and treat stroke or systemic embolism such as venous thromboembolism. Although bleeding is the most common complication of anticoagulants, only a few studies have addressed the safety of direct oral anticoagulants in East Asian patients. In this study, we investigated the risk factors for bleeding in Japanese patients receiving edoxaban. A retrospective review of the records of 198 patients who received 30 mg/d edoxaban in our hospital between April 2015 and March 2017 was performed. Subsequently, these patients were followed up to 1 year. Seven (3.5%) and 22 (11.1%) patients developed major bleeding and clinically relevant bleeding, respectively. In the univariate Cox regression analyses, low baseline hemoglobin levels (p = 0.002) and low baseline creatinine clearance (p = 0.020) were significantly associated with major bleeding. Multivariate Cox regression analysis revealed that a low baseline hemoglobin level was a significant risk factor for major bleeding and clinically relevant bleeding [hazard ratio 1.67 per 1 g/dL decrease (95% confidence interval 1.14-2.56, p = 0.008) and hazard ratio 1.31 per 1 g/dL decrease (95% confidence interval 1.06-1.62, p = 0.013), respectively]. Baseline hemoglobin level in quartiles also showed a quartile-dependent decrease in major bleeding and clinically relevant bleeding event. These results suggest that low baseline hemoglobin level is a significant risk factor for both major bleeding and clinically relevant bleeding in Japanese patients receiving edoxaban. Thus, these patients should be carefully monitored. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|